Jul 26, 2007
- Jul 27, 2007
|
CBI's 3rd Annual Obesity Drug Development Summit
Arlington, VA
Ronald Landbloom, M.D., Vice President of Medical and Regulatory Affairs at Orexigen, will discuss a summary of clinical trial results to date on Contrave™, the Company's lead obesity drug candidate.
|